MedTrace Logo

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

NCT00242268 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2005-12-07

No results posted yet for this study

Summary

The purpose of this study is to determine if using Avonex in combination with Zocor is a safe and effective therapy for subjects with relapsing remitting multiple sclerosis.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

Simvastatin

Sponsors & Collaborators

  • Biogen

    collaborator INDUSTRY

  • Alabama Neurology Associates, PC

    lead OTHER

Principal Investigators

  • Emily S. Riser, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242268 on ClinicalTrials.gov